The investment follows a period of technological and commercial progress at AAX Biotech, including the implementation of advanced automation to enhance platform scalability and several new collaborations, among them one with global pharmaceutical company Daiichi Sankyo, it states.

“This investment marks the next phase of platform development and expansion,” said Daniel X Johansson, CEO and CSO of AAX Biotech. “With Trio Impact Invest’s support, we can scale our proprietary platforms, broaden their impact across antibody discovery and development, and strengthen collaborations with new and existing partners.”

Trio Impact Invest’s investment will be allocated to platform advancement and continued development of industry partnerships.

“We’re thrilled to make our first investment from Trio Impact Invest in AAX Biotech, backing a team whose enabling technology can meaningfully improve how antibody-based medicines are discovered and optimized,” said Siimon Vaske, CEO of Trio Impact Invest AB. “AAX combines strong scientific capability with a clear roadmap to scale its proprietary platform and drive impact through collaborations and continued technology development.”